Skip to main content
Clinical Trials/NCT05416411
NCT05416411
Recruiting
N/A

Preoperative RESpiratory Training and MOBilization to Prevent Postoperative Pulmonary Complications in Patients Undergoing Thoracic Surgery (RESMOB): A Multi-center Randomized Controlled Trial

Istanbul University3 sites in 1 country436 target enrollmentJuly 20, 2022

Overview

Phase
N/A
Intervention
Not specified
Conditions
Postoperative Complications
Sponsor
Istanbul University
Enrollment
436
Locations
3
Primary Endpoint
The incidence of postoperative pulmonary complications
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

Postoperative pulmonary complications (PPCs) are the most frequent complications occurring in patients undergoing thoracic surgery and they are associated with prolonged hospital stay, decreased survival and expanding medical costs. Implementation of structured and supervised exercise programs including endurance training (ET), respiratory muscle training (RMT) or a combination of both, within the short waiting period before surgery, has been shown to enhance patients' physical fitness, to provide protective effects against PPCs and therefore to spare health care resources by shortening intensive care unit (ICU) and hospital lengths of stay. More recently, a simple intervention consisting in patient's instruction and education about modifiable risk factors, optimal breathing pattern and the impact of physical exercise has emerged as a simple alternative intervention prevent PPCs, although the evidence is inconclusive.

Therefore, the investigators propose a multicentre randomized, open, blinded end point controlled trial testing the hypothesis that preoperative education and instruction focused on breathing exercise and endurance training reduce the occurrence of PPCs in patients undergoing thoracic or abdominal surgery.

Patients with Intermediate-to-high risks factors for PPCs will be randomized on a 1:1 basis into an intervention arm and a usual care arm (Control group). In the Education group, patients will be asked to use a flow resistive device (One set of 30 repetitions, two times a day and to increase their daily physical activities (> 5'000 steps or equivalent) until surgery. Primary study endpoint will be the incidence of PPCs (e.g., atelectasis, pneumonia, respiratory failure) according to the European Perioperative Clinical Outcome definitions. Secondary outcomes will include non-respiratory complications, utilization of hospital resources (e.g., hospital length of stay, ICU admission),and preoperative changes in maximal inspiratory pressure [MIP]. Assuming a rate of 39% PPCs in the controls and a possible reduction to 26% in the intervention group, enrollment of 203 patients per group will provide 80% power with an alpha value of 0.05. Taking into account dropouts (5%) and in-hospital mortality rate (2%), a total of 436 surgical patients will be enrolled.

Registry
clinicaltrials.gov
Start Date
July 20, 2022
End Date
July 10, 2024
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Emre Sertaç Bingül

Medical Doctor, Lecturer

Istanbul University

Eligibility Criteria

Inclusion Criteria

  • Adult patients (\> 18 years)
  • Risk factors for PPCs (ARISCAT score \>27)
  • Elective intra-abdominal surgery or intrathoracic surgery via an open or minimally-invasive approach, expected to last \> 120 min.

Exclusion Criteria

  • Patients unable to understand the instructions and/or to perform the proposed training program (i.e., poor comprehension, chest pain)
  • COPD GOLD Grade III and IV, lung fibrosis, documented bullae, severe emphysema, pneumothorax
  • Patient with chest pain or at risk of pneumothorax
  • Previous lung surgery
  • Bilateral lung procedures
  • Emergent surgery or organ transplant
  • Planned mechanical ventilation after surgery
  • Uncontrolled asthma
  • Coronary heart disease with angina grade 3 or 4 Canadian Cardiovascular Society
  • documented pulmonary arterial hypertension \>25mmHg mean pulmonary arterial pressure (PAP) at rest or \> 40 mmHg systolic PAP (estimated by ultrasound)

Outcomes

Primary Outcomes

The incidence of postoperative pulmonary complications

Time Frame: Up to postoperative 5 days

Postoperative pulmonary complications will be investigated during the postoperative 5 days. These complications are named according to the European Perioperative Clinical Outcome (EPCO) definitions (Respiratory failure, aspiration pneumonitis, pneumonia, ARDS, pneumothorax, atelectasis, bronchospasm)

Secondary Outcomes

  • Length of stay in hospital(Up to 15 days)
  • Preoperative MIP change(7 days)
  • Visual Analog Scale thoracic coughing pain(Up to 5 days)
  • Visual Analog Scale dyspnea(Up to 5 days)
  • Visual Analog Scale thoracic rest pain(Up to 5 days)

Study Sites (3)

Loading locations...

Similar Trials